Foghorn Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 9, 2021 and accepted by EDGAR at Nov 9, 2021, 16:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $41.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $606.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-07-01 to 2021-09-30 | $20.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-01-01 to 2021-09-30 | $57.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$26.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$72.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-07-01 to 2021-09-30 | $499.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2021-01-01 to 2021-09-30 | $1.5m | us-gaap:InterestExpense |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$26.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | −$72.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | −$0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-09-30 | −$1.96 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-07-01 to 2021-09-30 | −$0.71 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-09-30 | −$1.96 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-07-01 to 2021-09-30 | 36,971,767 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-01-01 to 2021-09-30 | 36,879,392 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$62.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $3.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-09-30 | $57.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $124.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $186.1m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $19.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $105.1m | us-gaap:Liabilities |
| Long-term debt | At period end2021-09-30 | $20.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2021-09-30 | $81.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-21-022556. Last ingested by Listed: Nov 9, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.